Answer
Menveo prevents invasive disease caused by Neisseria meningitidis groups A, C, W-135 and Y and is indicated for children from 2 years of age, adolescents and adults at risk of exposure, in accordance with official recommendations.
Sources for this answer
- Menveo Group A,C,W135 and Y conjugate vaccineGlaxoSmithKline UK · emc · SmPC §4.1 Therapeutic Indications · Version 16Document updated
Sources checked